{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:03:27Z","timestamp":1789621407425,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NCI","award":["P30 CA077598"],"award-info":[{"award-number":["P30 CA077598"]}]},{"name":"DOD","award":["W81XWH-22-2-0025"],"award-info":[{"award-number":["W81XWH-22-2-0025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer subtypes harboring androgen receptor (AR) alterations have distinct AR biology that may impact response to therapy. We hypothesized that patients harboring AR T878A would have superior responses to AR pathway inhibitor (ARPI) therapy based on prior preclinical data. We utilized a large genomic-clinical database to identify mAPMR patients with AR T878A, AR L702H and AR amplification and performed a matched assessment of ARPI treatment outcomes using real-world surrogate endpoints for treatment response. Among AR T878A patients treated with enzalutamide, time to treatment discontinuation (TTD) was longer relative to patients with AR L702H (8 mo (95% CI 4.6\u201344 mo) vs. 3.5 mo (95% CI 2.3\u20135.5 mo) log-rank p &lt; 0.0001) or AR amplification (7.7 mo (95% CI 4.7\u201315.8 mo) vs. 4.8 mo (95% CI 4\u20135.1 mo) (log-rank p = 0.0034). Among the AR T878A patients treated with abiraterone, TTD was not significantly different relative to patients with AR L702H, but longer relative to patients with AR amplification (7.1 mo (95% CI 5\u20138.5 mo) vs. 4.2 mo (95% CI 3.5\u20135.4 mo) (log-rank p = 0.037). This study provides hypothesis generating evidence that outcomes for patients with AR LBD mutations may differ by mutation subtype. AR T878A may be relatively more sensitive to ARPI treatment than AR L702H or amplified AR.<\/jats:p>","DOI":"10.3390\/ijms27188199","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:31:57Z","timestamp":1789464717000},"page":"8199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-997X","authenticated-orcid":false,"given":"Matthew","family":"Siskin","sequence":"first","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, 160 E 34th Street, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Jayati","family":"Saha","sequence":"additional","affiliation":[{"name":"Guardant Health, 3100 Hanover St., Palo Alto, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota, 909 Fulton Street SE, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-3213","authenticated-orcid":false,"given":"Alessandro","family":"Leal","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, 160 E 34th Street, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-700X","authenticated-orcid":false,"given":"Samuel","family":"Parry","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, 160 E 34th Street, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3419-4723","authenticated-orcid":false,"given":"David R.","family":"Wise","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, 160 E 34th Street, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Le, T.K., Duong, Q.H., Baylot, V., Fargette, C., Baboudjian, M., Colleaux, L., Taieb, D., and Rocchi, P. (2023). Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. Cancers, 15.","DOI":"10.3390\/cancers15205047"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/pros.24356","article-title":"Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer","volume":"82","author":"Kwan","year":"2022","journal-title":"Prostate"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of Androgen Receptor in Prostate Cancer: A Review","volume":"37","author":"Fujita","year":"2019","journal-title":"World J. Mens Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2300330","DOI":"10.1200\/PO.23.00330","article-title":"Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative Clinical Genomics of Advanced Prostate Cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/path.5652","article-title":"Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer","volume":"254","author":"Porter","year":"2021","journal-title":"J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/PO.20.00047","article-title":"Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer","volume":"4","author":"Dang","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/PO.20.00084","article-title":"A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer","volume":"4","author":"Tolmeijer","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrurol.2014.345","article-title":"Switching and withdrawing hormonal agents for castration-resistant prostate cancer","volume":"12","author":"Lorente","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1073\/pnas.081565498","article-title":"Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone","volume":"98","author":"Sack","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1074\/jbc.M109.039958","article-title":"Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H","volume":"285","author":"Molier","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijbiomac.2022.07.058","article-title":"Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients","volume":"218","author":"Khan","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13059-015-0864-1","article-title":"Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients","volume":"17","author":"Lallous","year":"2016","journal-title":"Genome Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00227","article-title":"Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer","volume":"3","author":"Torquato","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41391-024-00805-3","article-title":"Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration","volume":"28","author":"Zengin","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_20","first-page":"EVIDoa2300171","article-title":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Petrylak, D.P., McKean, M., Lang, J.M., Gao, X., Dreicer, R., Geynisman, D.M., Stewart, T.F., Gandhi, M., Appleman, L.J., and Dorff, T.B. (2024, January 29). ARV-766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Initial Results of a Phase 1\/2 Study. Proceedings of the ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.5011"},{"key":"ref_22","unstructured":"Boyle, J., and Owens, K. (2023). Potential of Arvinas\u2019 PROTAC\u00ae AR Degraders Reinforced by 11.1 Months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC, Arvinas."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.37765\/ajmc.2024.89606","article-title":"Systemic treatments for advanced prostate cancer: Relationship between health insurance plan and treatment costs","volume":"30","author":"Kaye","year":"2024","journal-title":"Am. J. Manag. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer","volume":"3","author":"Stewart","year":"2019","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.2453","article-title":"The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies","volume":"111","author":"Rivera","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Siskin, M., Saha, J., Antonarakis, E.S., Leal, A., Parry, S., Tsai, J., and Wise, D.R. (2025, January 28). Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and AR T878A alterations treated with enzalutamide. Proceedings of the ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2025.43.16_suppl.5053"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:25:40Z","timestamp":1789619140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":28,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188199"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188199","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}